Cite
HARVARD Citation
Merle, P. et al. (2019). Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial. Lancet gastroenterology and hepatology. pp. 454-465. [Online].